Modification of kidney barrier function by the urokinase receptor
- PMID: 18084301
- DOI: 10.1038/nm1696
Modification of kidney barrier function by the urokinase receptor
Abstract
Podocyte dysfunction, represented by foot process effacement and proteinuria, is often the starting point for progressive kidney disease. Therapies aimed at the cellular level of the disease are currently not available. Here we show that induction of urokinase receptor (uPAR) signaling in podocytes leads to foot process effacement and urinary protein loss via a mechanism that includes lipid-dependent activation of alphavbeta3 integrin. Mice lacking uPAR (Plaur-/-) are protected from lipopolysaccharide (LPS)-mediated proteinuria but develop disease after expression of a constitutively active beta3 integrin. Gene transfer studies reveal a prerequisite for uPAR expression in podocytes, but not in endothelial cells, for the development of LPS-mediated proteinuria. Mechanistically, uPAR is required to activate alphavbeta3 integrin in podocytes, promoting cell motility and activation of the small GTPases Cdc42 and Rac1. Blockade of alphavbeta3 integrin reduces podocyte motility in vitro and lowers proteinuria in mice. Our findings show a physiological role for uPAR signaling in the regulation of kidney permeability.
Similar articles
-
Amiloride off-target effect inhibits podocyte urokinase receptor expression and reduces proteinuria.Nephrol Dial Transplant. 2012 May;27(5):1746-55. doi: 10.1093/ndt/gfr612. Epub 2011 Nov 9. Nephrol Dial Transplant. 2012. PMID: 22076430
-
1,25-dihydroxyvitamin D(3) inhibits podocyte uPAR expression and reduces proteinuria.PLoS One. 2013 May 31;8(5):e64912. doi: 10.1371/journal.pone.0064912. Print 2013. PLoS One. 2013. PMID: 23741418 Free PMC article.
-
The calcineurin-NFAT pathway allows for urokinase receptor-mediated beta3 integrin signaling to cause podocyte injury.J Mol Med (Berl). 2012 Dec;90(12):1407-20. doi: 10.1007/s00109-012-0960-6. Epub 2012 Sep 27. J Mol Med (Berl). 2012. PMID: 23015147 Free PMC article.
-
suPAR and chronic kidney disease-a podocyte story.Pflugers Arch. 2017 Aug;469(7-8):1017-1020. doi: 10.1007/s00424-017-2026-7. Epub 2017 Jul 8. Pflugers Arch. 2017. PMID: 28689240 Review.
-
Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.Stem Cells. 1997;15(6):398-408. doi: 10.1002/stem.150398. Stem Cells. 1997. PMID: 9402652 Review.
Cited by
-
Podocyte biology and pathogenesis of kidney disease.Annu Rev Med. 2013;64:357-66. doi: 10.1146/annurev-med-050311-163340. Epub 2012 Nov 26. Annu Rev Med. 2013. PMID: 23190150 Free PMC article. Review.
-
Abnormal Crosstalk between Endothelial Cells and Podocytes Mediates Tyrosine Kinase Inhibitor (TKI)-Induced Nephrotoxicity.Cells. 2021 Apr 12;10(4):869. doi: 10.3390/cells10040869. Cells. 2021. PMID: 33921219 Free PMC article. Review.
-
Drug discovery in focal and segmental glomerulosclerosis.Kidney Int. 2016 Jun;89(6):1211-20. doi: 10.1016/j.kint.2015.12.058. Epub 2016 Apr 23. Kidney Int. 2016. PMID: 27165834 Free PMC article. Review.
-
Effect of mycophenolic acid in experimental, nontransplant glomerular diseases: new mechanisms beyond immune cells.Pediatr Nephrol. 2017 Aug;32(8):1315-1322. doi: 10.1007/s00467-016-3437-y. Epub 2016 Jun 16. Pediatr Nephrol. 2017. PMID: 27312386 Review.
-
Soluble Urokinase Plasminogen Activator Receptor Levels Are Associated with Severity of Fibrosis in Patients with Primary Sclerosing Cholangitis.J Clin Med. 2022 Apr 28;11(9):2479. doi: 10.3390/jcm11092479. J Clin Med. 2022. PMID: 35566603 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous
